Analyst picks & changes
Analyst picks & changes
| Company | Bank | Analyst | Coverage | Opinion | Wk cls | 1/19 cls |
| Actelion (SWX:ATLN) | ING Bank | Mark Clark | New | Sell | 6% | CHF273.5 |
| Lehman | Peter Welford | Price target | Overweight | |||
| Clark set a CHF220 target. He thinks Tracleer bosentan to treat pulmonary arterial hypertension (PAH) will soon face serious competition from ambrisentan, for which Gilead (GILD) submitted an NDA to FDA last | ||||||
